Physician profile
Madhat A Arnouk
NPI 1154560944
$7,083.74
in general payments reported to CMS, 2019-2025
39 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $403 · 2021: $992 · 2022: $1,795 · 2023: $1,205 · 2024: $971 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.70 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,283.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Edwards Lifesciences Corporation | $1,239.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $767.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.52 | 2020-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $354.67 | 2019-2025 | Fasenra, Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $306.05 | 2023-2025 | Lumryz |
| Inari Medical, INC. | $216.17 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Harmony Biosciences LLC | $213.25 | 2020-2024 | Wakix |
| Mylan Specialty L.P. | $167.97 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $159.46 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $153.17 | 2023-2025 | Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $151.96 | 2021-2024 | Glassia |
| Grifols USA, LLC | $146.52 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Axsome Therapeutics, INC. | $129.31 | 2023-2024 | Sunosi |
| La Jolla Pharmaceutical Company | $124.07 | 2024 | Giapreza |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhat Arnouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.